Conditions: Major Depressive Disorder
Keywords: Major Depressive Disorder MDD Inadequate Response to Antidepressant Therapy Channel blocker of the NMDA class of glutamate receptors
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 542
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants. AZD6765 is a channel blocker of the N-methyl-D-aspartate (NMDA) class of glutamate receptors.

Detailed description:
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: AZD6765 iv intervention 2: AZD6765 iv intervention 3: Placebo
Intervention descriptions: intervention 1: 50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion. intervention 2: 100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion. intervention 3: 0.9 sodium chloride \[normal saline\] solution for injection by iv infusion

Protocol document: